Canada - English - Health Canada

omega laboratories limited - allergenic extract non-pollen - solution - 40000unit - allergenic extract non-pollen 40000unit - allergenic extracts

Canada - English - Health Canada

omega laboratories limited - allergenic extract non-pollen - liquid - 40000unit - allergenic extract non-pollen 40000unit - allergenic extracts

Canada - English - Health Canada

omega laboratories limited - allergenic extract non-pollen - liquid - 40000unit - allergenic extract non-pollen 40000unit - allergenic extracts

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 1000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - poa pratensis, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; phleum pratense, quantity: 20 %; dactylis glomerata, quantity: 20 %; lolium perenne, quantity: 20 % - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - lolium perenne, quantity: 20 %; phleum pratense, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; dactylis glomerata, quantity: 20 %; poa pratensis, quantity: 20 % - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Canada - English - Health Canada

greer laboratories inc - non pollen - liquid - 40000unit - non pollen 40000unit - allergenic extracts

Canada - English - Health Canada

stallergenes canada inc - grass pollen allergen extract - tablet - 100unit - grass pollen allergen extract 100unit - allergenic extracts

Canada - English - Health Canada

stallergenes canada inc - grass pollen allergen extract - tablet - 300unit - grass pollen allergen extract 300unit - allergenic extracts

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - aspergillus fumigatus 0.05 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t